Ziegler Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Ziegler Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,725	Closed	-$619K	–	431
2023 Q1	$619K	Buy	26,725 +259	+1%	+$6.17K	0.02%	337
2022 Q4	$693K	Buy	26,466 +686	+3%	+$15.2K	0.03%	327
2022 Q3	$507K	Buy	+25,780	New	+$517K	0.02%	346

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ziegler Capital Management's KDNY Position: Q2 2023 in Review

Ziegler Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 26,725 shares — an estimated $619K sold.

Ziegler Capital Management first reported a position in KDNY in Q3 2022 and held it in 3 quarters. The position peaked at $693K in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Ziegler Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ziegler Capital Management sold 26,725 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $619K.
Ziegler Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Ziegler Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $693K in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Ziegler Capital Management's 13F filing for Q2 2023, filed 25 Jul 2023.